Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
Harald Murck, Matthias C Braunisch, Carsten Konrad...
https://pubmed.ncbi.nlm.nih.gov/30300165/Actively Recruiting
Led by Philipps University Marburg · Updated on 2025-12-08
80
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating how different forms of depression respond to treatment by studying specific biomarkers linked to therapy resistance. This trial focuses on enoxolone, a molecule derived from licorice, which may influence biomarkers like aldosterone and cortisol in body fluids, blood pressure, and inflammation markers. The study aims to see if these biomarkers can predict whether patients respond better to enoxolone compared to a placebo, and to explore how these markers change with treatment and relate to clinical outcomes. Participants will be randomly assigned to receive either 100 mg of enoxolone or a placebo capsule taken once daily in the evening. The study includes a broad range of patients to compare those with higher or lower levels of specific biomarkers such as systolic blood pressure and the urine aldosteronecortisol ratio. Optional assessments include brain imaging and measures of white matter integrity. The trial is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. During the study, participants will have their blood pressure, urine, and blood samples collected to measure aldosterone, cortisol, sodium, potassium, and inflammation markers such as C-reactive protein. Additional assessments include heart rate variability, sleep duration, salt preference, and depression ratings over a four-week period. Researchers will monitor safety and clinical response throughout, with the primary outcome focusing on changes in depression severity related to biomarker levels.
CONDITIONS
Enoxolone in Major Depression - Biomarker-outcome Relationship
U
Ulrich Schu, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Philipps University Marburg
Lead Sponsor
Slovak Academy of Sciences
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants take one capsule of either enoxolone or placebo each evening to study its effects on depression and related biomarkers.
Weekly visits for up to 4 weeks
Duration - Up to several weeks after treatment
Participants are monitored after treatment to assess changes in depression symptoms and related biomarkers.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Harald Murck, Matthias C Braunisch, Carsten Konrad...
https://pubmed.ncbi.nlm.nih.gov/30300165/Harald Murck, Lisa Lehr, Johannes Hahn...
https://pubmed.ncbi.nlm.nih.gov/33362613/Jan Engelmann, Harald Murck, Stefanie Wagner...
https://pubmed.ncbi.nlm.nih.gov/34985381/Harald Murck
https://pubmed.ncbi.nlm.nih.gov/41155634/Harald Murck, Benjamin Luerweg, Johannes Hahn...
https://pubmed.ncbi.nlm.nih.gov/32306867/Philipps University Marburg
Lead Sponsor
Slovak Academy of Sciences
Collaborating Sponsor